Non-Regulatory

September 11, 2023

Affibody’s Partner ACELYRIN Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa

• The primary endpoint of HiSCR75 at week 16 did not meet statistical significance in the Non-Responder Imputation (NRI) primary analysis. • HiSCR75 did meet statistical significance at week 16...

Read more

Non-Regulatory

August 30, 2023

Data demonstrating that Affibody’s PET imaging agent ABY-025 can be used to predict therapeutic response will be presented at EANM

Solna, Sweden, August 30, 2023. Affibody AB (“Affibody”) today announced the presentation of data from patients in a clinical study of the PET imaging agent 68Ga-ABY-025 for non-invasive quantification...

Read more

Non-Regulatory

June 30, 2023

First ten HER2-low patients dosed in Phase 2 basket trial using Affibody’s PET imaging agent ABY-025

Solna, Sweden, June 30, 2023. Affibody AB (“Affibody”) today announced that the first ten patients have been dosed in a Phase 2 clinical basket study of the PET imaging...

Read more

Non-Regulatory

April 11, 2023

Positive Long-term Results with Izokibep in Psoriatic Arthritis

• Affibody’s partner ACELYRIN, INC today announced 46 weeks Phase 2 data where izokibep demonstrated high levels of response across psoriatic arthritis disease manifestations.• Long-term data build on statistically...

Read more

Non-Regulatory

March 18, 2023

Izokibep Phase 2b/3 Hidradenitis Suppurativa Data Presented at the 2023 American Academy of Dermatology Annual Meeting

• At 12 weeks, 57% of patients achieved HiSCR75, 38% achieved HiSCR90 and 33% achieved HiSCR100. • Safety results were consistent with previous trials of izokibep, with no increased...

Read more

Non-Regulatory

January 5, 2023

Positive Top-line Clinical Data for Izokibep in Hidradenitis Suppurativa

Solna, Sweden, January 5, 2023. Affibody’s partner ACELYRIN, Inc. today announced top-line 12-week open label data from a Phase 2b/3 trial of izokibep in patients with moderate-to-severe Hidradenitis Suppurativa...

Read more

Non-Regulatory

January 4, 2023

First HER2-low patients enrolled in Phase 2 basket trial using Affibody’s PET imaging agent ABY-025

Solna, Sweden, January 4, 2023. Affibody AB (“Affibody”) today announced that the first patients have been dosed in a Phase 2 clinical basket study of the PET imaging agent...

Read more

Non-Regulatory

December 23, 2022

Affibody signs €20 million loan agreement with the EIB to finance the development of next generation’s biopharmaceuticals against cancer and inflammatory diseases

Solna, Sweden, December 23, 2022. Affibody Medical AB (“Affibody”) today announced that the European Investment Bank, EIB, backed by the InvestEU programme, has provided a €20 million venture debt...

Read more

Non-Regulatory

November 8, 2022

Affibody Announce Positive Additional Izokibep Phase 2 Data in Patients with Psoriatic Arthritis (PsA) will be Presented at American College of Rheumatology (ACR) Convergence 2022

Solna, Sweden, November 8, 2022. Affibody today announced that positive additional data from a phase 2 trial of izokibep in psoriatic arthritis will be presented at the ACR Convergence...

Read more